Member Info for miavoce

Hi VanVan

we know that Genmab are interested in a further Glymab and that there is work ongoing with another company to determine if Scancell's tech works with theirs, and no doubt there are other discussion underway since the new Business Development Director came on board. The next deal can't be too far away.

IMO the fundraise was done to enable then to get to the end of the iSCIB1+ phase 2 as this will put them in position for the best possible deal.

AN invested in the fundraise at a significantly higher price that this.

Should get interims next week with an update on trials and other progress.

Sangijuelas1

if you knew how CellSearch worked and its capabilities you would realise why Angle shareholders are not remotely concerned about it.

Directors bought at 80p. Confident of future prospects I guess.

Banshee's on the other site made the point about ctDNA analysis being much quicker than CTC DNA analysis due to the 2 hours taken to separate the CTC's and clean the machine. I don't see this as an obstacle. Consider the following:-

- If a lab has 5 parsortix machines used in parallel they could do 5 CTC DNA analyses every 3 hours.

- Lets say the lab charges $1500 for the CTC DNA separation and analysis, of which they attribute $500 for the CTC separation stage.

- So every 3 hours simply for the separation process they can make 5 x $500 (i.e.$2500) minus the cost of 5 cassettes ($500) and the cost of the lab technician ($150).

- So every 3 hours they can make $1850 profit.

- if the lab works 6 days a week for 9 hours per day this equates to the lab making just over $1.7m profit per year doing CTC separations from just 5 parsortix machines in one lab.

- Angle make $468k from the sale of the cassettes.

And this is from a single lab with just 5 machines. A lot of potential profit for the lab which would surely encourage labs to adopt the technology and offer the service.

It doesn't take much imagination to see how much revenue could flow from the adoption of CTC DNA analysis alongside ctDNA analysis.

I guess most of us have seen the stellar rise of Angle today (and I know a number of us hold shares). Wouldn't it have been great to buy Angle at 11p just a few trading days ago ! Well, don't be left in the same position regarding Scancell, regretting not buying at 11p.

'Yes. Anytime now I would imagine. However the directors refuse to be drawn on whether it will be Ovarian or Prostate first.'

I guess this means they are probably running neck and neck and therefore we should get one shortly after the other....

Redmile have increased the number of shares they hold but have a smaller percentage of the company due to the expanded total shares in issue.

Big year for Angle next year IMO. Will be a star in your portfolio.

JustThinkItThrough

the standalone device can't be used make any diagnostic/prognostic claims for CTCs because its job is to get the CTC's from patient blood - analysis of those CTC's using other tools then has to take place for diagnosis / prognosis to be performed. Absolutely no reason why this can't happen.

Regarding research us, particularly in clinical trials, this could well grow into a significant business in its own right. Review previous Angle presentations to get a sense of the potential scale.

Same to you Thompi, we are due a good year next year that is for sure !!

Indeed Thompi, looks like most will be missed (although to be fair I think they have hit 2 - the PD-L1 and the Portrait+). Let's see what this week brings. I am however very optimistic for 2024.

I'm expecting 2024 to be commercially transformative for Angle with revenue being multiples of that in 2023. This revenue growth will be underpinned by multiple commercial deals and the coming to market of new products and service. I expect to exit 2024 with an SP which is multiples of that with which we leave 2023.

Some may disagree with the above, which is fine, but I strongly believe the above will materialise.

Thanks Burble

Hi Burble, thanks for the info ref the 3R's.

Do you have any idea how long the animal testing would typically take ?

Thanks

Keiny1 - I agree, the most likely end game IMO is a takeover, hopefully in the price range you suggest.

I think we are all in agreement that there are great prospects for a very much increased SP purely off the back of iSCIBi+, certainly in excess of £1 once things mature and possibly much more.

Hi RuckRover

the $300m would indeed be pure profit in that Scancell will have no costs associated with that income (other than some limited admin to receive and account for the money). Whether Scancell choose to use some of this money to funds the development of other products is a separate point. The development of those products would itself accrue value to the company.